Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

216.45CHF
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
CHF216.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,903,811
52-wk High
CHF255.00
52-wk Low
CHF206.35

Select another date:

Tue, Jun 19 2018

Photo

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

ZURICH/LONDON Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group's ability to personalize cancer care.

UPDATE 2-Roche pays $2.4 bln for rest of cancer expert Foundation Medicine

* Echoes past biotech buy-outs at Flat Iron and Genentech (Adds more on personalised cancer care, analyst comment)

Roche to pay $2.4 bln to buy rest of Foundation Medicine

ZURICH, June 19 Roche Holding AG has agreed to pay $137 per share to buy the rest of Foundation Medicine (FMI), valuing the U.S. genomic profiling group at $5.3 billion, the partners said on Tuesday.

Roche SMA drug shines in study as costly new therapies advance

ZURICH A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

Roche SMA drug shines in study as costly new therapies advance

ZURICH, June 18 A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

BRIEF-Roche Says Plans To Launch Coaguchek Vantus System

* ROCHE - PLANS TO LAUNCH COAGUCHEK VANTUS SYSTEM, EXPECTED TO BE COMMERCIALLY AVAILABLE IN U.S. IN SUMMER OF 2018 Source text for Eikon: Further company coverage:

Roche gets priority review from FDA for Hemlibra

ZURICH, June 5 Roche has been given fast-track review by the U.S. Food and Drug Administration (FDA) for its Hemlibra treatment for people with a form of haemophilia, the Swiss drugmaker said on Tuesday.

Roche's Perjeta wins approval in Europe for expanded use

ZURICH Roche's on Friday won European Union approval for its Perjeta medicine to treat a type of breast cancer whose sufferers are at a high risk of re-occurrence, the Swiss drugmaker said in a statement.

Roche's Perjeta wins approval in Europe for expanded use

ZURICH, June 1 Roche's on Friday won European Union approval for its Perjeta medicine to treat a type of breast cancer whose sufferers are at a high risk of re-occurrence, the Swiss drugmaker said in a statement.

EMA recommends restrictions on Merck, Roche immunotherapies

ZURICH The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

Select another date: